← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyStandard DatabasestalePhase 2
DC vaccine (DC vaccine)
David Bartlett·Metastatic Renal Cell Carcinoma
31 trials·t½ 53 h
Overview
Program
DC vaccine
Overview
Company
David Bartlett
Overview
Modality
ANTIBODY
Overview
Target
Metastatic Renal Cell Carcinoma
Overview
Indication
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface; Malignant Peritoneal Mesothelioma
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
PK/PD
Half-life
53 h
Toxicology
Major finding
Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial.. Locally advanced, unresectable esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite definitive chemoradiotherapy (CRT), and no standard maintenance therapy currently…
Clinical
Safety signal
Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial.. Locally advanced, unresectable esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite definitive chemoradiotherapy (CRT), and no standard maintenance therapy currently…
Clinical
Program phase
PHASE_2